160 related articles for article (PubMed ID: 30051293)
1. Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?
Tada Y; Inokuchi S; Maruyama A; Suematsu R; Sakai M; Sadanaga Y; Ono N; Arinobu Y; Koarada S
Rheumatol Int; 2019 Jan; 39(1):97-104. PubMed ID: 30051293
[TBL] [Abstract][Full Text] [Related]
2. The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease.
Nigrovic PA; de Benedetti F; Kimura Y; Lovell DJ; Vastert SJ
Pediatr Rheumatol Online J; 2024 Jan; 21(Suppl 1):114. PubMed ID: 38183114
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of emapalumab in macrophage activation syndrome.
De Benedetti F; Grom AA; Brogan PA; Bracaglia C; Pardeo M; Marucci G; Eleftheriou D; Papadopoulou C; Schulert GS; Quartier P; Antón J; Laveille C; Frederiksen R; Asnaghi V; Ballabio M; Jacqmin P; de Min C
Ann Rheum Dis; 2023 Jun; 82(6):857-865. PubMed ID: 37001971
[TBL] [Abstract][Full Text] [Related]
4. Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease Continuum.
Kontzias A; Petryna O; Nakasato P; Efthimiou P
Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):45-57. PubMed ID: 38756937
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil activation biomarker pentraxin 3 for diagnosis and monitoring of macrophage activation syndrome occurrence in adult-onset Still's disease.
Zhu D; Chen L; Meng J; Wang M; Ma Y; Chen X; Xiao Y; Yi D; Shi H; Sun Y; Liu H; Cheng X; Su Y; Ye J; Chi H; Zhou Z; Yang C; Teng J; Jia J; Hu Q
J Autoimmun; 2024 Apr; 144():103182. PubMed ID: 38460457
[TBL] [Abstract][Full Text] [Related]
6. An unusual case of adult-onset still's disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome.
Fung WW; Chao AC; Pang WF; Wong RS; Chow KM; Szeto CC
BMC Nephrol; 2024 May; 25(1):164. PubMed ID: 38745129
[TBL] [Abstract][Full Text] [Related]
7. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Boom V; Anton J; Lahdenne P; Quartier P; Ravelli A; Wulffraat NM; Vastert SJ
Pediatr Rheumatol Online J; 2015 Dec; 13():55. PubMed ID: 26634252
[TBL] [Abstract][Full Text] [Related]
8. Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
Huang S; Liu Y; Yan W; Zhang T; Wang P; Zhu M; Zhang X; Zhou P; Fan Z; Yu H
Pediatr Rheumatol Online J; 2024 May; 22(1):58. PubMed ID: 38783316
[TBL] [Abstract][Full Text] [Related]
9. A Recurrent Case of Adult-onset Still's Disease with Concurrent Acalculous Cholecystitis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis Successfully Treated with Combination Immunosuppressive Therapy.
Arai Y; Ishikawa Y; Abe K; Kato Y; Abe D; Fujiwara M; Kita Y
Intern Med; 2021 Jun; 60(12):1955-1961. PubMed ID: 33518559
[TBL] [Abstract][Full Text] [Related]
10. Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
Hoffmann MC; Cavalli G; Fadle N; Cantoni E; Regitz E; Fleser O; Klemm P; Zaks M; Stöger E; Campochiaro C; Tomelleri A; Baldissera E; Bittenbring JT; Zimmer V; Pfeifer J; Fischer Y; Preuss KD; Bewarder M; Thurner B; Fuehner S; Foell D; Dagna L; Kessel C; Thurner L
J Clin Immunol; 2024 Jan; 44(2):45. PubMed ID: 38231276
[TBL] [Abstract][Full Text] [Related]
11. Biallelic mutations in the CFHR genes underlying atypical hemolytic uremic syndrome in a patient with catastrophic adult-onset Still's disease and recurrent macrophage activation syndrome: A case report.
Dillemans L; Bekhuis Y; Betrains A; Yu K; van Hemelen M; Pörtner N; De Somer L; Matthys P; Breckpot J; Tousseyn T; Peetermans M; Proost P; Wouters C; Vanderschueren S
Clin Immunol; 2023 Dec; 257():109815. PubMed ID: 37898413
[TBL] [Abstract][Full Text] [Related]
12. Adult-onset Still's disease complicated by macrophage activation syndrome during pregnancy: a case-based review.
Wise L; Zell M
Clin Rheumatol; 2023 Nov; 42(11):3159-3166. PubMed ID: 37322269
[TBL] [Abstract][Full Text] [Related]
13. Treatment of systemic juvenile idiopathic arthritis.
Hinze CH; Foell D; Kessel C
Nat Rev Rheumatol; 2023 Dec; 19(12):778-789. PubMed ID: 37923864
[TBL] [Abstract][Full Text] [Related]
14. Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still's Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience.
Adachi S; Takase-Minegishi K; Maeda A; Nagai H; Horita N; Yoshimi R; Kirino Y; Nakajima H
Rheumatol Ther; 2023 Dec; 10(6):1623-1636. PubMed ID: 37794210
[TBL] [Abstract][Full Text] [Related]
15. Systemic juvenile idiopathic arthritis-associated lung disease: A retrospective cohort study.
Belozerov KE; Solomatina NM; Isupova EA; Kuznetsova AA; Kostik MM
World J Clin Pediatr; 2024 Mar; 13(1):88912. PubMed ID: 38596441
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease: A preclinical study in mice and a pilot study in humans.
Koga T; Sumiyoshi R; Tsuji Y; Kodama K; Endo Y; Furukawa K; Kawakami A
Clin Immunol; 2023 Dec; 257():109846. PubMed ID: 38007033
[TBL] [Abstract][Full Text] [Related]
17. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
Shakoory B; Geerlinks A; Wilejto M; Kernan K; Hines M; Romano M; Piskin D; Ravelli A; Sinha R; Aletaha D; Allen C; Bassiri H; Behrens EM; Carcillo J; Carl L; Chatham W; Cohen JI; Cron RQ; Drewniak E; Grom AA; Henderson LA; Horne A; Jordan MB; Nichols KE; Schulert G; Vastert S; Demirkaya E; Goldbach-Mansky R; de Benedetti F; Marsh RA; Canna SW;
Ann Rheum Dis; 2023 Oct; 82(10):1271-1285. PubMed ID: 37487610
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of macrophage activation syndrome and treatment progression.
Dong Y; Wang T; Wu H
Front Immunol; 2024; 15():1389710. PubMed ID: 38736876
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.
Brossard P; Laveille C
Rheumatol Ther; 2024 Jun; 11(3):869-880. PubMed ID: 38662147
[TBL] [Abstract][Full Text] [Related]
20. Application of the Yamaguchi criteria for classification of "suspected" systemic juvenile idiopathic arthritis (sJIA).
Kumar S; Kunhiraman DS; Rajam L
Pediatr Rheumatol Online J; 2012 Nov; 10(1):40. PubMed ID: 23176399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
